- Rating
- 1
- Confidence
- 2
- Informativeness
- 2
- Presentation
- 2
- Soundness
- 1
Read review
Paper summary
scBridge transfers drug response supervision from bulk transcriptomics to the unlabeled single cell level via separate beta-VAEs, covariance alignment, bidirectional stochastic transport, cycle consistency and pseudo-label refinement. Across 12 datasets the average AUROC/AUPR/F1 are 0.867/0.878/0.770 compared to scDEAL's 0.793/0.802/0.758.
Critical strengths
-
Major problem and promising results. Transferring bulk supervision is a solution to the problem of the lack of single cell response labels. The reported improvements in AUROC and AUPR across drugs and cancer types are very encouraging.
-
Useful supporting analyses (component ablations, dataset level results, subsampling and noise experiments, biological attribution).
Critical weaknesses
-
The predictor has unresolved inconsistencies, and preservation of response correspondence is not established. Equation 7 defines the backward prediction as , but Algorithm 1 subtracts it. Under this convention, the update should add it. The prediction head is trained with a fine-tuned bulk encoder, while transport uses a separate frozen encoder. Their compatibility is not explained.
-
Matching distributions doesn't guarantee that sensitive cells map to sensitive cells. You can have separate encoders with independently selected genes, covariance alignment and cycle consistency and still end up with mappings that swap class correspondence.
-
Noise free inference keeps the learned drift but does not generally preserve the distributions of the stochastic process. A matched deterministic baseline is required in order to isolate the benefit of stochastic training.
Questions for authors
-
How does Equation 7 satisfy Algorithm 1? Which encoder features are used to train the prediction head and how are they kept in line with the transport space?
-
Please provide the standard deviations across the five runs, the split identifiers and the exact model/baseline settings. Were the baselines evaluated on the same splits? How were the hyperparameters, checkpoints and classification thresholds selected in the context of the stated target-label restriction?
-
How are the bulk labels and drug specific thresholds defined? How are the single cell response labels actually constructed in the case of GSE241225? What is the positive class and what is the F1 averaging convention?
-
How is noise-free inference justified? Does the gain hold up against matched deterministic transport?
-
What actually tests the preservation of response correspondence beyond just distribution matching? A controlled correspondence experiment or one based on shared gene representation? How sensitive are the results to encoder initialisation?